Outpace Bio Announces Multiple Presentations at the 2024 American Association of Cancer Research (AACR) Annual Meeting
“T cell therapies have so far demonstrated modest efficacy against solid tumors, limited in part by poor expansion and functional persistence,” said Outpace CSO Aaron Foster, PhD .
- “T cell therapies have so far demonstrated modest efficacy against solid tumors, limited in part by poor expansion and functional persistence,” said Outpace CSO Aaron Foster, PhD .
- “Our lead program OPB-101 incorporates multiple Outpace technologies that together drive durable responses in stringent preclinical models at very low treatment doses.
- These attributes could potentially address the key barriers to efficacy and safety observed in previous solid tumor clinical studies.”
Details of the poster presentations during the AACR annual meeting are below. - OPB-101 is the company’s lead pipeline program and is on track for an IND submission in Q4 2024.